HERE ARE OUR SPEAKERS
Stay tuned for more details
Prof. Dr. Beate Koksch
Freie Universität Berlin, Germany
Introduction of the element fluorine into peptide, protein and cell engineering; Peptide misfolding and aggregation; Phage display technology; Peptide drug development; Biomaterials; Rational design of catalytically active peptides
Prof. Assaf Friedler
Keynote Speaker
The Hebrew University of Jerusalem, Israel
Friedler's lab uses peptides for the quantitative biophysical and structural analysis of PPI in health and disease. Based on this, his research group develop lead peptides that modulate PPI for therapeutic purposes
Keynote Speaker
Prof. Robert Konrat
University of Vienna, Austria
we introduced a new theoretical conception of protein structural biology (meta-structure) that can be used for protein sequence-to-function annotation and drug design. A hallmark of our research is the integrative application of this novel conception and sophisticated NMR spectroscopy directed towards a better understanding of fundamental biological processes.
Dr. Nir Qvit
Bar-Ilan University, Israel
The Qvit lab is interested in the identification of molecular modulators of protein-protein interaction using bioinformatics analysis, peptide and protein chemistry, and system-wide biological assays
Prof. Dr. Ines Neundorf
University of Cologne, Germany
​​
Membrane-active peptides: antimicrobial peptides / cell-penetrating peptides / organelle targeting sequences; peptide synthesis and modification; peptides in tumor diagnosis and therapy
Prof. Marta De Zotti
University of Padova, Italy
​​
Research Interests:
ANTIMICROBIAL/ANTITUMOR PEPTIDES
PEPTIDE-BASED MOLECULAR DEVICES: TOWARDS NEW SMART MATERIALS.
Prof. Christopher J. Serpell
University College London, UK
Serpell lab encompasses nucleic acid, natural product, and polymer chemistry.
Prof. Gideon Schreiber
Keynote Speaker
Weizmann Institute of Science, Rehovot, Israel
Schreiber lab studies the basic physico-chemical principles governing the kinetics, thermodynamics, and specificity of protein-protein interactions.
Prof. Hausch Felix
Keynote Speaker
Technical University Darmstadt, Germany
We study
-
Rational design of active ingredients
-
Clarification and validation of new pharmacological mechanisms of action
-
Synthesis of macro- or poly-cyclic substances to control the bioactive conformation
-
Quantitative understanding of the protein-ligand interaction
-
Development of FKBP51 inhibitors as new antidepressants, analgesics and/or anti-obesity drugs
Dr. Ora Furman
The Hebrew University of Jerusalem, Israel
The Schueler-Furman lab developed state of the art, leading modeling protocols that have significantly extended the number of interactions that can be modeled accurately on the one hand, and highlighted basic principles of binding and communication on the other.
Prof. Chaim Gilon
The Hebrew University of Jerusalem, Israel
The Gilon lab develop novel approach for peptide cyclization as well as Conversion of PPI hot spots into orally available drug candidates
Prof. Christian Becker
University of Vienna, Austria
​​
The Becker lab develops and uses chemical as well as biochemical means to generate peptides and proteins with otherwise unattainable (posttranslational) modifications to address fundamental biochemical as well as biomedical and biotechnological challenges.